Cholangiocarcinoma Market, By Cancer Type [Extrahepatic Cholangiocarcinoma (Perihilar, Distal), Intrahepatic Cholangiocarcinoma], By Therapy Type [Targeted Drug Therapy (Pemigatinib, Ivosidenib, Futibatinib, Infigratinib), Chemotherapy (5-Fluorouracil, Ge

Cholangiocarcinoma Market, By Cancer Type [Extrahepatic Cholangiocarcinoma (Perihilar, Distal), Intrahepatic Cholangiocarcinoma], By Therapy Type [Targeted Drug Therapy (Pemigatinib, Ivosidenib, Futibatinib, Infigratinib), Chemotherapy (5-Fluorouracil, Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Immunotherapy (Pembrolizumab, and Others), and Others (Pain Medications and Others)], By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Cholangiocarcinoma Market, By Cancer Type [Extrahepatic Cholangiocarcinoma (Perihilar, Distal), Intrahepatic Cholangiocarcinoma], By Therapy Type [Targeted Drug Therapy (Pemigatinib, Ivosidenib, Futibatinib, Infigratinib), Chemotherapy (5-Fluorouracil, Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Immunotherapy (Pembrolizumab, and Others), and Others (Pain Medications and Others)], By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that originates in the bile ducts. Cholangiocarcinoma is a relatively rare cancer which needs to be diagnosed at an advanced stage because the symptoms of the cancer often appears late until the disease is at its well-advanced stage. The exact cause of cholangiocarcinoma is unknown, but it is believed that factors such as chronic inflammation of the bile ducts, certain infections (e.g., with the liver fluke parasite), and certain risk factors (e.g., smoking, heavy alcohol use) may increase the risk of developing this cancer. Diagnosis typically involves a combination of imaging studies, such as CT scans, MRIs, and endoscopic retrograde cholangiopancreatography (ERCP), as well as tissue biopsies to confirm the presence of cancer. Treatment options for cholangiocarcinoma depends on the stage of the cancer and the patient's overall health. The treatments are surgery, radiation therapy, chemotherapy, and other targeted therapies. Prognosis for cholangiocarcinoma varies depending on the stage at which it is diagnosed, and early detection and intervention are crucial for improving outcomes.

Market Dynamics

Key players are engaged in research and development activities which is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, in February 2022, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, a Germany-based clinical research institution, initiated a clinical trial titled “A Phase II Study of Immunotherapy with Durvalumab and Tremelimumab in Combination with Capecitabine or Without Capecitabine in Adjuvant Situation for Biliary Tract Cancer”. The study is currently in phase 2 which is estimated to get completed by December 2024.

Key features of the study:

• This report provides an in-depth analysis of the global cholangiocarcinoma market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cholangiocarcinoma market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include BridgeBio Inc., Sanofi, Eisai Co., Ltd., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Incyte, TRISALUS LIFE SCIENCES, INC., GENFIT, Johnson & Johnson Private Limited, Bliss Biopharmaceutical, Novartis AG, LES LABORATOIRES SERVIER, F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris.Inc), AstraZeneca, Compass Therapeutics, Inc, Otsuka Holdings Co., Ltd., and Senhwa Biosciences, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global cholangiocarcinoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cholangiocarcinoma market

Detailed Segmentation:

• Global Cholangiocarcinoma Market, By Cancer Type:
• Perihilar
• Distal
• Extrahepatic Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma
• Global Cholangiocarcinoma Market, By Therapy Type:
• Targeted Drug Therapy

Pemigatinib

Ivosidenib

Futibatinib

Infigratinib

• Chemotherapy

5-fluorouracil

Gemcitabine

Cisplatin

Capecitabine

Oxaliplatin

• Immunotherapy

Pembrolizumab

Others (Late phase pipeline drugs)

• Others (Pain Medications and others)
• By Route of Administration:
• Oral
• Subcutaneous
• Intravenous
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• E-commerce
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles
• BridgeBio Inc.
• Sanofi
• Eisai Co., Ltd.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceuticals Ltd.
• Fresenius SE & Co. KGaA
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Incyte
• TRISALUS LIFE SCIENCES, INC.
• GENFIT
• Johnson & Johnson Private Limited
• Novartis AG
• LES LABORATOIRES SERVIER
• F. Hoffmann-La Roche Ltd
• Mylan N.V. (Viatris.Inc)
• AstraZeneca
• Compass Therapeutics, Inc
• Otsuka Holdings Co., Ltd.
• Senhwa Biosciences, Inc.